Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02973997
Title Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

thyroid gland follicular carcinoma

thyroid gland cancer

thyroid gland papillary carcinoma

thyroid gland Hurthle cell carcinoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.